Atsutaka Masuda

Kurume, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Rapid regression of advanced hepatic fibrosis in a patient with metabolic dysfunction-associated steatotic liver disease and severe obesity: a case report highlighting lifestyle-induced NETosis activation through serum proteomic analysis.

Rapid regression of advanced hepatic fibrosis in a patient with metabolic dysfunction-associated steatotic liver disease and severe obesity: a case report highlighting lifestyle-induced NETosis activation through serum proteomic analysis.

Journal: Clinical journal of gastroenterology

Published: January 21, 2026

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma.

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma.

Journal: Cells

Published: December 19, 2024

Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.

Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.

Journal: Regenerative therapy

Published: March 20, 2024

Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice.

Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice.

Journal: Cytotherapy

Published: December 25, 2023

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.

Journal: Hepatology international

Published: July 20, 2023

Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.

Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.

Journal: Hepatology international

Published: May 04, 2023

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.

Journal: iScience

Published: April 18, 2023

Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.

Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.

Journal: Gastro hep advances

Published: March 23, 2023

Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.

Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.

Journal: Cancer communications (London, England)

Published: April 27, 2022

Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.

Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.

Journal: Oncology letters

Published: December 27, 2021

DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.

DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Journal: Gastro hep advances

Published: October 07, 2021

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments.

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments.

Journal: Translational oncology

Published: June 23, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026